The role of GM-CSF in the treatment of acute myeloid leukemia.
After a first study showed that GM-CSF following chemotherapy effectively accelerated neutrophil recovery and reduced early mortality in high risk patients with AML, a second study was begun in which GM-CSF was applied preceding chemotherapy and continuing until neutrophil recovery in the initial 5 chemotherapy courses for patients with newly diagnosed AML. The CR rate in patients of 16-75 (median 50) years was 75% in GM-CSF patients and 84% in controls. GM-CSF patients showed a trend to more frequent rapid blast clearance and fewer persistent leukemias and a significantly superior remission duration as of this update two-and-a-half years after the study started. It should be shown later by this study whether GM-CSF multiple course priming and longterm administration adds to the cure rate of patients with AML.
Büchner
T
T
Department of Internal Medicine, University of Münster, Germany.
Hiddemann
W
W
Wörmann
B
B
Rottmann
R
R
Maschmeyer
G
G
Ludwig
W D
WD
Zühlsdorf
M
M
Buntkirchen
K
K
Sander
A
A
Aswald
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008875:Middle Aged
D016178:Granulocyte-Macrophage Colony-Stimulating Factor